| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 121 | 옥심기를 가교로 하는, 불소화 프로페닐기가 치환된 프로페노익 에스테르 및 아미드 화합물, 이의 제조방법 및 이를 포함하는 살균제 조성물 | KR1019990033724 | 1999-08-16 | KR1020010017962A | 2001-03-05 | 김범태; 박노균; 최경자; 박창식 |
| PURPOSE: Provided is a novel propenoic ester and amide compound being cross-linked by an oxime group and substituted by a fluorinated prophenyl group. The novel compound has excellent sterilizability and a broad antibacterial activity. Also, its preparation method and a bactericide composition including the same are provided. CONSTITUTION: A novel propenoic ester compound being cross-linked by an oxime group and substituted by a fluorinated prophenyl group is represented by the formula (1), wherein X is CH or N ; Y is O or NH ; R1 is hydrogen, C1-4 alkyl or C1-4 alkyl in which more than one group is substituted with halogen ; and R2 is phenyl, C1-4 alkyl,, C1-4 alkyl substituted with halogen, C1-4 alkoxy, methylenedioxy or phenyl in which more than one group is substituted with halogen. The novel propenoic ester compound is prepared by reacting a brominated compound of the formula (2) and an oxime compound of the formula (3) in the presence of a base, to obtain a compound of the formula (4); debenzylating the resultant compound, to obtain a phenolic ester compound of chemical formula (5); and reacting the resultant compound with a fluorinated prophenyl compound of the formula (6) in the presence of a base. | ||||||
| 122 | 옥심기를 가교로 하는, 불소화 비닐기가 치환된 프로페노익 에스테르 및 아미드 화합물, 이의 제조방법 및 이를 포함하는 살균제 조성물 | KR1019990033722 | 1999-08-16 | KR1020010017960A | 2001-03-05 | 김범태; 박노균; 김진철; 박창식 |
| PURPOSE: Provided is a novel propenoic ester and amide compound being cross-linked by an oxime group and substituted by a fluorinated vinyl group. The novel compound has excellent sterilizability and a broad antibacterial activity. Also, its preparation method and a bactericide composition including these are provided. CONSTITUTION: A novel propenoic ester compound being cross-linked by an oxime group and substituted by a fluorinated vinyl group is represented by the formula (1), wherein X is CH or N ; Y is O or NH ; R1 is hydrogen, C1-4 alkyl or C1-4 alkyl substituted with halogen ; and R2 is phenyl, C1-4 alkyl,, C1-4 alkyl substituted with halogen, C1-4 alkoxy, methylenedioxy, phenyl in which more than one group is substituted with halogen or naphthalene. The novel propenoic ester compound is prepared by reacting a brominated compound of the formula (2) and an oxime compound of the formula (3) in the presence of a base, to obtain compound of the formula (4); debenzylating the resultant compound, to obtain phenolic ester compound of the formula (5); and reacting the resultant compound with a fluorinated vinyl compound of the formula (6) in the presence of a base. | ||||||
| 123 | 저장안정성 아릴 니트론 조성물 및 이의 제조방법 | KR1019850009971 | 1985-12-30 | KR1019860004845A | 1986-07-14 | 마이크로,인코포레이티드 |
| 124 | N-니트로소 화합물의 탈니트로소화 방법 | KR1019780001102 | 1978-04-15 | KR100013807B1 | 1983-02-16 | 로우렌스제이므즈로스; 죠오지에넬로치아렐로 |
| 125 | N-니트로소 화합물의 탈니트로소화 방법 | KR1019780001102 | 1978-04-15 | KR1019820002078B1 | 1982-11-04 | 로우렌스제이므즈로스; 죠오지에넬로치아렐로 |
| Title compds.(IV); R'=alkyl, cycloalkyl, haloalkyl, alkoxyalkyl; R"=alkyl, cycloalkyl, monohaloalkyl, alkoxyalkyl) were denitrosoated by treating with ketone (II; Ra=lower alkyl, Ph, substituted Ph; R6=lower alkyl) at 20-120≦̸C in the presence of HCI or HBr and, optionally, an inert organic solvent. Thus, 96g of a soln. contg. 38.2wt.% N-(1-ethyl-propyl)-2, 6-dinitro-3, 4,-xylidine and 13.4wt.% N-(1-ethyl-propyl)-N-nitro-2, 6-dinitro-3, 4-xylidine was added in 14.7g concd. HCI and 2.5g Et2CO, and the mixt. was heated 4 hr at 80-85≦̸C to give 51.4g solid product. | ||||||
| 126 | Two-step synthesis of pyrrole compounds from furan compounds | US17202481 | 2021-03-16 | US11608317B2 | 2023-03-21 | Kenneth M. Lassen |
| Pyrrole compounds are produced by contacting a furan compound, a solid acid catalyst, and water to form a reaction mixture containing a γ-dicarbonyl compound, and then contacting the γ-dicarbonyl compound with ammonia or an ammonium salt to form a reaction product mixture containing the pyrrole compound. A representative pyrrole compound that can be synthesized using these processes is 2,5-dimethylpyrrole. | ||||||
| 127 | Process for producing amino acids from precursors obtained by anaerobic fermentation from fermentable biomass | US15053854 | 2016-02-25 | US09701619B2 | 2017-07-11 | Régis Nouaille; Jérémy Pessiot; Marie Thieulin |
| The process for producing amino acids from volatile fatty acid (VFA) molecules, referred to as precursors, produced by anaerobic fermentation from fermentable biomass, comprises at least the following steps: a) extracting the volatile fatty acid (VFA) molecules, without stopping the fermentation, via an extraction means chosen from means that are, at least, insoluble in the fermentation medium, b) collecting, outside the fermentation reactor, the volatile fatty acid (VFA) molecules once they have been extracted, c) synthesizing, by halogenation, using a type of volatile fatty acid (VFA) chosen from the volatile fatty acids collected in step b) and defined according to the desired type of amino acid, a given α-halo acid, d) synthesizing from this α-halo acid a defined amino acid. | ||||||
| 128 | 1H-QUINAZOLINE-2,4-DIONES | US13932173 | 2013-07-01 | US20130296332A1 | 2013-11-07 | Hans ALLGEIER; Yves AUBERSON; David CARCACHE; Philipp FLOERSHEIM; Christel GUIBOURDENCHE; Wolfgang FROESTL; Jörg KALLEN; Manuel KOLLER; Henri MATTES; Joachim NOZULAK; David ORAIN; Johanne RENAUD |
| The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed. | ||||||
| 129 | Process for the preparation of (R)-(−)-3-(carbamoylmethyl)-5-methylhexanoic acid and of pregabalin and synthesis intermediates | US12306980 | 2007-06-06 | US08563775B2 | 2013-10-22 | Annibale Salvi; Antonio Nardi; Bruno De Angelis |
| This invention relates to the preparation of (R)-(−)-3-(carbamoylmethyl)-5-methylhexanoic acid, in particular, the resolution of the acid racemate by means of salification with optically active amines and subsequent acidification to give the (R) enantiomer of the acid; this invention also concerns the salt intermediates formed with said amines and the conversion of said (R)-(−)-3-(carbamoylmethyl)-5-methylhexanoic acid into biologically active molecules such as pregabalin. | ||||||
| 130 | Doxorubicin adjuvants to reduce toxicity and methods for using the same | US12369657 | 2009-02-11 | US08227517B2 | 2012-07-24 | William A. Garland; Brian D. Frenzel |
| Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions. | ||||||
| 131 | Methods for concomitant administration of colchicine and macrolide antibiotics | US13110087 | 2011-05-18 | US08093298B2 | 2012-01-10 | Matthew W. Davis |
| Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | ||||||
| 132 | Methods for concomitant administration of colchicine and a second active agent | US13092459 | 2011-04-22 | US08093297B2 | 2012-01-10 | Matthew W. Davis |
| Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | ||||||
| 133 | OXIDISING AGENTS FOR ELASTOMER BONDING COMPOSITIONS | US13234919 | 2011-09-16 | US20120003501A1 | 2012-01-05 | Nigel Fay; Brendan J. Kneafsey; Darren Nolan; David P. Birkett; Susan Warren |
| Compositions comprising at least one copper salt, and an aromatic nitroso compound precursor are provided. The copper salt may oxidise the aromatic nitroso compound precursor to provide an aromatic nitroso compound. The compositions may find utility in polymer to metal, in particular, rubber to metal bonding. The aromatic nitroso compound precursor may be a nitrosobenzene/dinitrosobenzene precursor. The nitrosobenzene or dinitrosobenzene precursor may be at least one of a quinone oxime or a quinone dioxime. | ||||||
| 134 | Methods for concomitant administration of colchicine and macrolide antibiotics | US13110087 | 2011-05-18 | US08039516B2 | 2011-10-18 | Matthew W. Davis |
| Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | ||||||
| 135 | Colchicine compositions and methods | US12407980 | 2009-03-20 | US07964647B2 | 2011-06-21 | Matthew W. Davis |
| Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | ||||||
| 136 | SYNTHESIS OF NEW ORGANIC MATERIAL FOR POLYMERIC LIGHT EMITTING DIODE | US12147291 | 2008-06-26 | US20090322212A1 | 2009-12-31 | Giovanna Salzillo; Antonio Roviello; Giuseppina Roviello; Giuseppe Russo |
| New, highly photoluminescent compounds are described having structural formula (I) wherein: R1, R2, R3, R4, independently from each other, represent H; alkyl, alkenyl; aryl; —(CH2CH2—O)n—CH3. These compounds are highly photoluminescent and have high quantum yield; they have optimal plasticity characteristics and optimal miscibility with other amorphous polymers; they lead to the formation of thin, stable and uniform layers of photoluminescent material, obtainable by simple techniques of deposition from solution. A simple and high yield process is described for obtaining the aforesaid compounds. In addition, the use of the compounds of formula (I) and their polymer derivatives is described in the preparation of electroluminescent devices, for example LEDs. | ||||||
| 137 | Process For the Production of 2(2-Aminophenyl)-Bicylopropane Derivatives | US11815895 | 2006-02-20 | US20080161610A1 | 2008-07-03 | Harald Walter; Camilla Corsi; Josef Ehrenfreund; Clemens Lamberth; Hermann Schneider; Hans Tobler |
| The present invention relates to a process for the preparation of compounds of formula (I) wherein the substituents are as defined in claim 1, by a) reaction of a compound of formula (II) to form a compound of formula (III) b) reaction of that compound in the presence of a base to form a compound of formula (IV) c) conversion of that compound in the presence of a reducing agent into a compound of formula (I). | ||||||
| 138 | Functional thin film | US10508658 | 2003-03-26 | US20050240061A1 | 2005-10-27 | Tamotsu Takahashi; Kiyoshi Musha; Koichi Sakamaki; Yoshikazu Shoji |
| The present invention provides organic electroluminescent elements selected from polyacene derivatives represented by general formula (I) below: [wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, A1 and A2, which are the same or different, each represents hydrogen atom, a hydrocarbon group, etc., and n denotes an integer of not less than 1]. The organic electroluminescent elements of the present invention can provide materials for organic electroluminescent elements and organic electroluminescent elements, which are excellent in stability, durability, luminance and luminance efficiency. | ||||||
| 139 | C-nitroso compounds and use thereof | US11052777 | 2005-02-09 | US20050203295A1 | 2005-09-15 | Jonathan Stamler; Eric Toone |
| A C-nitroso compound having a molecular weight ranging from about 225 to about 1,000 (from about 225 to about 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is useful as an NO donor. When the compound is obtained from a carbon acid with a pKa less than about 10, it provides vascular relaxing effect when used at micromolar concentrations and this activity is potentiated by glutathione to be obtained at nanomolar concentrations. When the compound is obtained from a carbon acid with a pKa ranging from about 15 to about 20, vascular relaxing effect is obtained at nanomolar concentrations without glutathione. The compound is preferably water-soluble and preferably contains a carbon alpha to the nitrosylated carbon which is part of a ketone group. In one embodiment, the C-nitroso compound is obtained by nitrosylation of a conventional drug or such drug modified to modify the carbon acid pKa thereof When such drug is a nonsteroidal anti-inflammatory drug, the resulting C-nitroso compound functions as a COX-1 and COX-2 inhibitor without the deleterious effects associated with COX-1 inhibition but with the advantageous effects associated with COX-1 and COX-2 inhibition. One such C-nitroso compound is a nitrosoketoibuprofen. A specific example of this kind of compound is isolated as dimeric 2-[4′-(α-nitroso)isobutyrylphenyl]propionic acid. In another case, the C-nitroso compound contains the moiety where X is S, O or NR. One embodiment is directed to COX-2 inhibitors where a tertiary carbon atom and/or an oxygen atom and/or a sulfur atom is nitrosylated. | ||||||
| 140 | C-nitroso compounds and use thereof | US11052141 | 2005-02-08 | US20050187166A1 | 2005-08-25 | Jonathan Stamler; Eric Toone |
| A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is useful as an NO donor. When the compound is obtained from a carbon acid with a pKa less than about 10, it provides vascular relaxing effect when used at micromolar concentrations and this activity is potentiated by glutathione to be obtained at nanomolar concentrations. When the compound is obtained from a carbon acid with a pKa ranging from about 15 to about 20, vascular relaxing effect is obtained at nanomolar concentrations without glutathione. In another embodiment, a biocompatible polymer incorporates a C-nitroso moiety. | ||||||
QQ群二维码
意见反馈
意见反馈